← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 1997First marketed drug
Apr 1, 1990First NDA
Apr 1, 1990Last known activity
Aug 5, 2020
Acquired by AstraZeneca on Jun 19, 2007
Timeline
1980s
- Jan 1, 1988
MedImmune— Founded
1990s
- Dec 17, 1993
trimetrexate— NDA Secondary Org
- Jun 19, 1998
palivizumab— Marketing Organization
- Jun 19, 1998
palivizumab— NDA Organization
- Jan 1, 1999
US Bioscience— Acquired
2000s
- Dec 1, 2001
Aviron— Acquired
- Nov 18, 2005
Cellective Therapeutics— Acquired
- Jun 19, 2007
AstraZeneca— Acquired By
Drugs by trial phase (151 distinct, 333 trials)
Phase 4 (3 own, 1 via acquisition)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (85 own, 1 via acquisition)
Phase 1 (48 own, 4 via acquisition)
Other trials (0 own, 1 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- Adenocarcinoma
- Aggression
- Appendiceal Neoplasms
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Atherosclerosis
- Autoimmune Diseases
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Chickenpox
- Chronic Disease
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Dermatitis
- Dermatitis, Atopic
- Dermatomyositis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Eczema
- Esophageal Neoplasms
- Esophagitis
- Fatty Liver
- Fibrosis
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Glioma
- Graft vs Host Disease
- Head and Neck Neoplasms
- Healthcare-Associated Pneumonia
- Heart Defects, Congenital
- Heart Diseases
- HIV Infections
- Hodgkin Disease
- Hydronephrosis
- Hypersensitivity
- Idiopathic Pulmonary Fibrosis
- Infections
- Influenza, Human
- Kidney Diseases
- Kidney Neoplasms
- Leukemia
- Leukemia, Hairy Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Prolymphocytic
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell, Cutaneous
- Lymphoproliferative Disorders
- Melanoma
- Mesothelioma
- Mucositis
- Multiple Myeloma
- Multiple Sclerosis
- Myelodysplastic Syndromes
- Myocardial Ischemia
- Myositis
- Necrosis
- Neoplasm Metastasis
- Neoplasm, Residual
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neoplasms, Squamous Cell
- Neuromyelitis Optica
- Non-alcoholic Fatty Liver Disease
- Obesity
- Osteoarthritis
- Ovarian Neoplasms
- Overweight
- Papilloma
- Paramyxoviridae Infections
- Pelvic Neoplasms
- Pneumonia
- Pneumonia, Staphylococcal
Marketed drugs (5)
Subsidiaries (3 direct, 3 total across the full acquisition tree)
Recent trials (50)
- NCT03501615OfficialN/A—
- NCT04522323Lead sponsorPhase 1Aug 5, 2020
- NCT04261075Lead sponsorPhase 1Feb 17, 2020
- NCT04145193Lead sponsorPhase 2Jan 30, 2020
- NCT04208620CollaboratorPhase 1Jan 10, 2020
- NCT04019561Lead sponsorPhase 2Sep 25, 2019
- NCT04091373Lead sponsorPhase 1Sep 17, 2019
- NCT04068610Lead sponsorPhase 1/Phase 2Aug 29, 2019
- NCT03889275Lead sponsorPhase 1Jul 30, 2019
- NCT03889275OfficialPhase 1Jul 30, 2019
- NCT03946800OfficialPhase 1May 8, 2019
- NCT03946800Lead sponsorPhase 1May 8, 2019
- NCT03903718Lead sponsorPhase 2Apr 16, 2019
- NCT03794544Lead sponsorPhase 2Mar 8, 2019
- NCT03773172CollaboratorPhase 2Jan 31, 2019
Details
- Founded
- Gaithersburg, MD, US Jan 1, 1988
- First NDA
- Apr 1, 1990
- Last known activity
- Aug 5, 2020
Designations held
- Orphan drug